Increased in vitro uptake of the complement C3b in the serum of patients with Guillain-Barre syndrome, myasthenia gravis and dermatomyositis

Journal of Neuroimmunology

Volumn 71, Issue 1-2, 1996, Pages 227-229

  Basta, Milan ^a   Illa, Isabel ^a   Dalakas, Marinos C ^a  

^a Human Motor Control Section   (United States)

Author keywords

complement; neuromuscular disorders; quantitative assay

Indexed keywords

COMPLEMENT COMPONENT C3B; COMPLEMENT MEMBRANE ATTACK COMPLEX;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATOMYOSITIS; GUILLAIN BARRE SYNDROME; HUMAN; HUMAN CELL; MYASTHENIA GRAVIS; PRIORITY JOURNAL; SERUM;

COMPLEMENT ACTIVATION; COMPLEMENT C3B; DERMATOMYOSITIS; ERYTHROCYTES; HUMANS; MYASTHENIA GRAVIS; POLYRADICULONEUROPATHY;

EID: 0030560758     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(96)00133-6     Document Type: Article

References (16)

1. Basta M., Dalakas M.C. Mechanism of beneficial effect of high-dose intravenous immunoglobulin in patients with dermatomyositis (DM): Blockade of endomisial deposition of activated complement fragments. J. Clin. Invest. 94:1994;1729-1735.
2. Basta M., Langlois M.M., Frank M.M., Fries L.F. High-dose intravenous immunoglobulin modifies complement-mediated in-vivo clearance. Blood. 74:1989;326-333.
3. Basta M., Frank M.M., Fries L.F. IVIG does not affect the recognition phase of the classical complement pathway. Blood. 78:1991;700-702.
4. Basta M., Fries L.F., Frank M.M. High-dose intravenous immunogloculin (IVIG) inhibits in vitro uptake of C4 fragments onto sensitized erythrocytes. Blood. 77:1991;376-380.
5. Dalakas M.C. Polymyosistis, dermatomyositis and inclusion-body myositis. N. Engl. J. Med. 325:1991;1487-1498.
6. Dalakas M.C., Illa I., Dambrosia J.M.et al. A controlled trial of high-dose immune globulin infusions as treatment for dermatomyositis. N. Engl. J. Med. 329:1993;1993-2000.
7. Emslie-Smith A.M., Engel A.G. Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann. Neurol. 27:1990;343-356.
8. Frank, M.M. and Fries, L.F. (1989) Complement. In: W.E. Paul (Ed.), Fundamental Immunology. 2nd ed., Raven Press, New York, pp. 688-690.
9. Gaither, T.A. and Frank, M.M. (1979) Complement. In: J.B. Henry (Ed.): Clinical Diagnosis and Management by Laboratory Methods. Saunders, Philadelphia, p. 1253.
10. Gajdos P. Intravenous immune globulin in myasthenia gravis. Clin. Exp. Immunol. 97((Suppl.)):1994;49-51.
11. Hartung H.P., Pellard J.D., Harvey G.K., Toyka K.V. Immunopathogenesis and treatment of the Guillain-Barré Syndrome. Part II. Muscle and Nerve. 18:1995;154-164.
12. Koski C.L., Sanders M.E., Swoveland P.T., Lawley T.J., Shin M.L., Frank M.M., Joiner K.A. Activation of terminal components of complement in patients with Guillain-Barré syndrome and other demyelinating neuropathies. J. Clin. Invest. 80:1987;1492-1497.
13. Lisak, R.P. (Ed.) (1994) Handbook of myasthenia gravis and myasthenia syndrome. Marcel Dekker, New York, pp. 195-196, 228.
14. Nakano S., Engel A.G. Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients. Neurology. 43:1993;1167-1172.
15. Shapiro S.S., Wilk M.B. An analysis of variance test for normality (complete and samples). Biometrika. 52:1965;5911-611.
16. van de Meche F.G.A., Schmitz P.I.M. Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N. Engl. J. Med. 326:1992;1123-1129.